Clinical Trial Update: MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating MRD-guided BCMA/CD3 bispecific antibody treatment after stem cell transplant in newly diagnosed multiple myeloma; recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA/CD3 bispecific antibody

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING